1. Presented By Praful Ravi at 2016 ASCO Annual Meeting
Evolving changes in M-protein (M), quantitative involved immunoglobulin (Ig), and hemoglobin (Hb) to identify patients (pts) with ultra high-risk smoldering multiple myeloma (UHR-SMM)
Presented By Praful Ravi at 2016 ASCO Annual Meeting

2. Presented By Praful Ravi at 2016 ASCO Annual Meeting
Background
Presented By Praful Ravi at 2016 ASCO Annual Meeting

3. High-Risk Smoldering Myeloma
Presented By Praful Ravi at 2016 ASCO Annual Meeting

4. Evolving Pattern in Smoldering Myeloma
Presented By Praful Ravi at 2016 ASCO Annual Meeting

5. Presented By Praful Ravi at 2016 ASCO Annual Meeting
Slide 5
Presented By Praful Ravi at 2016 ASCO Annual Meeting

6. Presented By Praful Ravi at 2016 ASCO Annual Meeting
Objectives
Presented By Praful Ravi at 2016 ASCO Annual Meeting

7. Presented By Praful Ravi at 2016 ASCO Annual Meeting
Methods
Presented By Praful Ravi at 2016 ASCO Annual Meeting

8. Presented By Praful Ravi at 2016 ASCO Annual Meeting
Methods
Presented By Praful Ravi at 2016 ASCO Annual Meeting

9. Baseline Characteristics
Presented By Praful Ravi at 2016 ASCO Annual Meeting

10. Presented By Praful Ravi at 2016 ASCO Annual Meeting
Evolving Change
Presented By Praful Ravi at 2016 ASCO Annual Meeting

11. Predictors of Early (≤2yrs) Progression
Presented By Praful Ravi at 2016 ASCO Annual Meeting

12. Presented By Praful Ravi at 2016 ASCO Annual Meeting
Slide 12
Presented By Praful Ravi at 2016 ASCO Annual Meeting

13. Ultra High-Risk Smoldering Myeloma
Presented By Praful Ravi at 2016 ASCO Annual Meeting

14. Presented By Praful Ravi at 2016 ASCO Annual Meeting
Sensitivity Analyses
Presented By Praful Ravi at 2016 ASCO Annual Meeting

15. Presented By Praful Ravi at 2016 ASCO Annual Meeting
Conclusions
Presented By Praful Ravi at 2016 ASCO Annual Meeting

16. Presented By Praful Ravi at 2016 ASCO Annual Meeting
Acknowledgements
Presented By Praful Ravi at 2016 ASCO Annual Meeting